Want to see OMCL full AI Analyst Report?
OMCL Stock Chart & Stats
$41.00
-$0.05(-0.12%)
At close: 4:00 PM EDT
$41.00
-$0.05(-0.12%)
Day’s Range― - ―
52-Week Range$29.06 - $55.00
Previous CloseN/A
Volume116.00K
Average Volume (3M)719.86K
Market Cap
$1.69B
Enterprise Value$1.79K
Total Cash (Recent Filing)$292.17M
Total Debt (Recent Filing)$188.51M
Price to Earnings (P/E)41.4
Beta0.59
Next Earnings
Nov 04, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding45,478,910
10 Day Avg. Volume689,632
30 Day Avg. Volume719,864
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$58.33Price Target Upside42.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.94
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLeverage materially improved to roughly 0.16 with sizable equity relative to assets, giving the company financial flexibility. This cleaner balance sheet reduces refinancing risk, supports capital allocation (R&D, rollouts, buybacks) and underpins stability over the next 2–6 months.
Cash GenerationConsistently positive and growing free cash flow (≈$140M TTM) and strong operating cash flow provide durable internal funding for product shipments, services expansion and integration costs. This cash profile de-risks execution and supports reinvestment into SaaS and hardware rollouts.
Strategic Product & Commercial TractionNew Titan XT hardware and OmniSphere cloud platform represent structural product upgrades that can expand recurring services and create higher switching costs. Initial orders and reported pipeline (VA, major academic center) indicate scalable adoption potential and multi-year ARR upside.
Bears Say
Thin Net Margins And Profit VolatilityDespite EBITDA recovery, net margins are very slim and past losses highlight earnings volatility. Low net profitability leaves limited cushion for cost shocks or mix shifts, slowing return improvement and making operating leverage benefits vulnerable over the medium term.
Capital Approval / Adoption Pacing RiskLong, multi-quarter-to-multi-year hospital capital approval timelines create lumpy, back‑half weighted bookings and delayed revenue recognition. That structural pacing risk can compress near-term growth visibility and complicate working-capital and production planning over several quarters.
Tariff Headwind & Near-Term Liquidity ReductionA persistent tariff cost (~$12M) plus a materially lower cash balance after large debt repayment reduces near-term liquidity and raises sensitivity to cost or timing shocks. Lower reserves limit flexibility for opportunistic investments or to smooth pacing issues from product rollouts.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $29.06 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.69B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Nov 04, 2026 which is in 95 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Jul 30, 2026. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.468 by $0.472.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.43.
How many shares outstanding does Omnicell have?
Omnicell has 45,478,910 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.94 in its last earnings report, beating expectations of $0.468. Following the earnings report the stock price went down -10.362%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.33 (42.28% Upside)
$58.33 (42.28% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.83%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OMCL Company Deck
OMCL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.View all OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$58.33
▲(42.28% Upside)
Technical Analysis
Ownership Overview
3.01% Insiders
29.49% Mutual Funds
0.80% Other Institutional Investors
32.26% Public Companies and
Individual Investors